These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 36587121)
41. The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy. Xu L; Xie X; Luo Y Eur J Cell Biol; 2021 Mar; 100(2):151153. PubMed ID: 33476912 [TBL] [Abstract][Full Text] [Related]
42. Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors. Musick M; Yu X Immunol Res; 2022 Aug; 70(4):432-440. PubMed ID: 35486115 [TBL] [Abstract][Full Text] [Related]
43. Antitumor therapy for breast cancer: Focus on tumor-associated macrophages and nanosized drug delivery systems. Zhan C; Jin Y; Xu X; Shao J; Jin C Cancer Med; 2023 May; 12(10):11049-11072. PubMed ID: 36794651 [TBL] [Abstract][Full Text] [Related]
44. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260 [TBL] [Abstract][Full Text] [Related]
45. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. Chamseddine AN; Assi T; Mir O; Chouaib S Pharmacol Ther; 2022 Mar; 231():107986. PubMed ID: 34481812 [TBL] [Abstract][Full Text] [Related]
46. The Roles and Targeting of Tumor-Associated Macrophages. Li Y; Wang R; Gao Q Front Biosci (Landmark Ed); 2023 Sep; 28(9):207. PubMed ID: 37796698 [TBL] [Abstract][Full Text] [Related]
47. Tumor-Associated Macrophages: Reasons to Be Cheerful, Reasons to Be Fearful. Szulc-Kielbik I; Kielbik M Exp Suppl; 2022; 113():107-140. PubMed ID: 35165862 [TBL] [Abstract][Full Text] [Related]
48. Lipid Metabolic Regulatory Crosstalk Between Cancer Cells and Tumor-Associated Macrophages. Liu S; Shen YY; Yin LY; Liu J; Zu X DNA Cell Biol; 2023 Aug; 42(8):445-455. PubMed ID: 37535386 [TBL] [Abstract][Full Text] [Related]
49. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective. Xiao Y; Zhang L; Zhu J; Zhang Y; Yang R; Yan J; Huang R; Zheng C; Xiao W; Huang C; Wang Y Biomed Pharmacother; 2021 Nov; 143():112105. PubMed ID: 34560533 [TBL] [Abstract][Full Text] [Related]
50. Targeting macrophages: a novel avenue for cancer drug discovery. Kumar S; Ramesh A; Kulkarni A Expert Opin Drug Discov; 2020 May; 15(5):561-574. PubMed ID: 32141351 [No Abstract] [Full Text] [Related]
51. Interaction of tumor‑associated macrophages with stromal and immune components in solid tumors: Research progress (Review). Kazakova A; Sudarskikh T; Kovalev O; Kzhyshkowska J; Larionova I Int J Oncol; 2023 Feb; 62(2):. PubMed ID: 36660926 [TBL] [Abstract][Full Text] [Related]
52. A Hierarchical Structured Fiber Device Remodeling the Acidic Tumor Microenvironment for Enhanced Cancer Immunotherapy. Li Y; Yuan R; Luo Y; Guo X; Yang G; Li X; Zhou S Adv Mater; 2023 May; 35(21):e2300216. PubMed ID: 36912443 [TBL] [Abstract][Full Text] [Related]
53. Targeting tumor-associated macrophages: A potential treatment for solid tumors. Chen Y; Jin H; Song Y; Huang T; Cao J; Tang Q; Zou Z J Cell Physiol; 2021 May; 236(5):3445-3465. PubMed ID: 33200401 [TBL] [Abstract][Full Text] [Related]
54. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes. Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579 [No Abstract] [Full Text] [Related]
55. The role of tumor-associated macrophage in breast cancer biology. Choi J; Gyamfi J; Jang H; Koo JS Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373 [TBL] [Abstract][Full Text] [Related]
56. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy. Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L Cells; 2022 May; 11(9):. PubMed ID: 35563889 [TBL] [Abstract][Full Text] [Related]
57. Tumor‑associated macrophages in lung cancer: Friend or foe? (Review). Xu F; Wei Y; Tang Z; Liu B; Dong J Mol Med Rep; 2020 Nov; 22(5):4107-4115. PubMed ID: 33000214 [TBL] [Abstract][Full Text] [Related]
58. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Chen D; Zhang X; Li Z; Zhu B Theranostics; 2021; 11(3):1016-1030. PubMed ID: 33391518 [TBL] [Abstract][Full Text] [Related]
59. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067 [TBL] [Abstract][Full Text] [Related]
60. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy. Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]